Mitochondrial Gene Therapy
Mitochondrial Gene Therapy
批准号:
8447582
负责人:
SHOUKHRAT M MITALIPOV
金额:
$57.42万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-08 至 2015-03-31
关键词:
AffectAgeAnimal ModelAssisted Reproductive TechnologyBiologicalBirthCell physiologyCellsChildCompetenceComplexControl AnimalCytoplasmDNADefectDevelopmentDiabetes MellitusDiagnosisDiseaseDisease ProgressionEmbryoEmbryo TransferEmbryonic DevelopmentEpigenetic ProcessEukaryotic CellFamilyFemaleFertilizationFertilization in VitroGenesGeneticGenetic CounselingGenomic ImprintingGoalsGrowth and Development functionHistonesHumanHusbandIn VitroInfantInfertilityInheritedInterventionKaryotypeLeadLightMacaca mulattaMalignant NeoplasmsMetaphaseMinorMitochondriaMitochondrial DNAMitochondrial DiseasesModelingMonkeysMutationMyopathyNeurodegenerative DisordersNewborn InfantNuclearOocytesOrganPatientsPregnancyPremature aging syndromePrimatesProceduresProductionProtocols documentationReplacement TherapyRiskRoleSafetyStagingSymptomsTechniquesTestingTissuesTransplantationVariantWorkbaseclinically relevantdesigndisease transmissioneggembryonic stem cellfree radical oxygengene replacement therapygene therapyhuman diseaseimprintimprovedinsightmitochondrial DNA mutationmitochondrial gene replacementmutantnonhuman primatenovelnovel strategiesoffspringpluripotencypostnatalpreimplantationprenatalpreventprogramspublic health relevancerepairedreproductivesegregationsperm celltransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Mutations in mitochondrial (mt)DNA are associated with a wide range of human diseases including premature aging, myopathies, neurodegenerative diseases, diabetes, cancer and infertility. In light of the fact that many of these disorders are dependent on the heteroplasmic state of the mtDNA and associated threshold effects, it is difficult to provide accurate genetic counseling based on preimplantation or prenatal genetic diagnoses. At present, there are no cures for mitochondrial disorders and available treatments only improve symptoms and slow disease progression. The main goal of this proposal is to generate important new insights concerning feasibility, efficacy and safety of novel reproductive options designed to minimize the occurrence of mtDNA- defects in a clinically relevant nonhuman primate model. Our main hypothesis is that mtDNA can be efficiently replaced by a novel approach, i.e., spindle transfer (ST) in mature metaphase II (MII) oocytes without interfering with subsequent nucleo-mtDNA compatibility and developmental competence. Our preliminary studies demonstrate the feasibility and efficacy of this approach in the rhesus monkey. We believe that reconstructed oocytes produced after spindle transfer will be nearly homoplasmic, capable of supporting normal fertilization and competent for full term development. To achieve this goal we propose the following specific aims: 1. Develop efficient mtDNA replacement approaches in rhesus monkey oocytes. Our working hypothesis is that unfertilized, mature MII-arrested oocytes are the most optimal stage for mtDNA interventions. We will explore several ST procedures and evaluate their impact on spindle integrity, fertilization and in vitro embryo development. We will also evaluate feasibility and efficacy of ST with cryopreserved oocytes. 2. Investigate developmental potential of reconstructed oocytes and assess mtDNA heteroplasmy and epigenetic profiles in ST offspring. Initially, we propose to derive embryonic stem (ES) cells and to examine karyotype, pluripotency, imprinting and mtDNA heteroplasmy in vitro. Next, we will evaluate the potential of reconstructed embryos to establish pregnancies and produce normal infants, the ultimate test before applications in humans. We will also investigate segregation of mtDNA variants in various tissues and organs of ST offspring. 3. Study growth and development of monkeys produced by ST and examine mtDNA transmission in the ST female germline. Our assumption is that mtDNA replacement therapy will not affect normal postnatal growth and development of ST offspring. We will study experimentally created monkeys from birth to age 5 in comparison to control animals. Due to the genetic bottleneck in the female germline, some offspring of heteroplasmic females may inherit a significant portion of mtDNA from the nuclear donor. Therefore, we will investigate mtDNA heteroplasmy in oocytes collected from ST females by creating embryos and ES cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reconstructing Somatic Chromosomes
-
批准号:10772559
-
项目类别:
-
资助金额:$65.99万
-
财政年份:2023
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Horizontal mtDNA Exchange
-
批准号:10356794
-
项目类别:
-
资助金额:$55.93万
-
财政年份:2019
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Horizontal mtDNA Exchange
-
批准号:9902293
-
项目类别:
-
资助金额:$55.93万
-
财政年份:2019
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Horizontal mtDNA Exchange
-
批准号:10584513
-
项目类别:
-
资助金额:$55.93万
-
财政年份:2019
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Mitochondrial Aging and Reprogramming
-
批准号:9142455
-
项目类别:
-
资助金额:$52.31万
-
财政年份:2015
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
CORRECTING MITOCHONDIRAL GENE MUTATIONS IN HUMAN OOCYTES
-
批准号:8357848
-
项目类别:
-
资助金额:$5.82万
-
财政年份:2011
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
ALTERED NUCLEAR TRANSFER
-
批准号:8357769
-
项目类别:
-
资助金额:$14.55万
-
财政年份:2011
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
HISTOCOMPATIBLE PRIMATE EMBYONIC STEM CELLS (ESCS)
-
批准号:8357828
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2011
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
DERIVING OOCYTES FROM EMBRYONIC STEM CELLS (ESCS)
-
批准号:8357829
-
项目类别:
-
资助金额:$4.36万
-
财政年份:2011
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
MITOCHONDRIAL GENE THEREAPY IN A MACAQUE MODEL
-
批准号:8357849
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2011
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Altered Nuclear Transfer
-
批准号:8013894
-
项目类别:
-
资助金额:$53.81万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
PRIMATE PLURIPOTENT CELLS FOR AUTOLOGOUS TRANSPLANTATION
-
批准号:8173333
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Altered Nuclear Transfer
-
批准号:8431435
-
项目类别:
-
资助金额:$52.91万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
GENETIC ANALYSIS OF GERM CELL FORMATION
-
批准号:8173332
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Altered Nuclear Transfer
-
批准号:8212330
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Mitochondrial Gene Therapy
-
批准号:8056813
-
项目类别:
-
资助金额:$61.86万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
DERIVING OOCYTES FROM ESCS
-
批准号:8173327
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Mitochondrial Gene Therapy
-
批准号:8241150
-
项目类别:
-
资助金额:$61.5万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Mitochondrial Gene Therapy
-
批准号:8644818
-
项目类别:
-
资助金额:$53.0万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
Mitochondrial Gene Therapy
-
批准号:7898222
-
项目类别:
-
资助金额:$64.35万
-
财政年份:2010
-
负责人:SHOUKHRAT M MITALIPOV
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: